The role of androgen in the development of sexual differences in pituitary responsiveness to gonadotropin releasing hormone (GnRH) agonist in the bullfrog, Rana catesbeiana.
Sexual differences in pituitary responsiveness to acute injection of gonadotropin-releasing hormone (GnRH) agonist, as measured by increments in plasma FSH and LH, were examined throughout development in the bullfrog, Rana catesbeiana. Untreated tadpoles, in various stages of metamorphosis, were unresponsive to GnRH agonist. Postmetamorphic males showed a progressive increase in the magnitude of pituitary response with age, whereas females remained relatively insensitive until after sexual maturation; males were always more responsive than females. Chronic (1-2.5 week) Silastic implants containing 5 alpha-dihydrotestosterone (DHT) significantly augmented the pituitary response (for both gonadotropins) in intact postmetamorphic females at all ages; a similar, though less pronounced, action of testosterone in subadult females may have been due to its conversion to DHT. (Silastic implants of comparable size always produced higher circulating levels of DHT in females than in males as was observed in previous studies with gonadectomized frogs.) DHT enhanced the responsiveness of intact tadpoles (sexes undetermined); only the treated tadpoles responded to the GnRH agonist. Supplemental DHT did not enhance pituitary response in intact males; in fact, it attenuated the response in FSH. GnRH responsiveness paralleled changes in pituitary gonadotropin content; pituitary content of FSH and LH was higher in males than females; it showed a marked increase with age from tadpole to adult; and it was increased by DHT treatment. The potentiating effect of DHT on GnRH responsiveness and the significantly higher levels of DHT observed in males of all ages suggest that the nonaromatizable androgen DHT may be responsible for the early establishment and maintenance of sexual dimorphism in pituitary GnRH responsiveness in the bullfrog.
D000818:Animals; D013196:Dihydrotestosterone / Q000097:blood / Q000494:pharmacology*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D007987:Gonadotropin-Releasing Hormone / Q000494:pharmacology*; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D008675:Metamorphosis, Biological / Q000187:drug effects; D010906:Pituitary Hormone-Releasing Hormones / Q000502:physiology*; D011892:Rana catesbeiana; D012733:Sex Differentiation / Q000187:drug effects*; D013739:Testosterone / Q000097:blood
D010906:Pituitary Hormone-Releasing Hormones; D013196:Dihydrotestosterone; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone